Primary Biliary Cholangitis clinical trials at UC Health
2 research studies open to eligible people
A Study of Experimental Baricitinib For People With Primary Biliary Cholangitis (destroyed liver bile ducts) Who Cannot Take UDCA
open to eligible people ages 18 years and up
This study evaluates the safety and efficacy of baricitinib in participants with primary biliary cholangitis (PBC) who do not respond or are unable to take ursodeoxycholic acid (UDCA).
at UC Davis
Primary Biliary Cholangitis with incomplete response or intolerant to ursodeoxycholic acid? Participate in a clinical trial
“Help us evaluate if a new investigational drug is safe and effective in the treatment of PBC”
open to eligible people ages 18-75
A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)
at UC Davis
Last updated: